Drugmaker Swedish Orphan Biovitrum said on Saturday it had entered into an agreement to acquire biotechnology company Arthrosi Therapeutics for $1.5 billion.
In a parallel world ruled by the sinister Magisterium, a battle rages over a mysterious particle called Dust. Can orphan Lyra ...
Dec 13 (Reuters) - Drugmaker Swedish Orphan Biovitrum said on Saturday it had agreed to acquire U.S.-based biotechnology company Arthrosi Therapeutics for up to $1.5 billion to strengthen its ...
Requiring just one trial will neither speed approvals nor support safety ...
Amgen’s (AMGN) blinatumomab was granted FDA orphan designation as a treatment of acute lymphoblastic leukemia, according to a post to the agency’s ...
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a clinical-stage biopharmaceutical company ...
According to Facebook posts, "The story has gone viral, with millions calling it 'the most meaningful tribute in modern ...
That era is ending. Policy reform, economic pressure, and patient empowerment have fractured that reality into three distinct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback